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Abstract: Despite improvements in treatment of different types of leukemia, not all patients 
respond optimally for a particular treatment. Some treatments will work better for some, while 
being harmful or ineffective for others. This is due to genetic variation in the form of single-
nucleotide polymorphisms (SNPs) that affect gene expression or function and cause inherited 
interindividual differences in the metabolism and disposition of drugs. Drug transporters are 
one of the determinants governing the pharmacokinetic profile of chemotherapeutic drugs. The 
ABCB1 transporter gene transports a wide range of drugs, including drugs used in leukemia 
treatment. Polymorphisms in the ABCB1 gene do affect intrinsic resistance and pharmacokinetics 
of several drugs used in leukemia treatment protocols and thereby affect the efficacy of treatment 
and event-free survival. This review focuses on the impact of three commonly occurring SNPs 
(1236C>T, 2677G>T/A, and 3435C>T) of ABCB1 on treatment response of various types of 
leukemia. From the literature available, some of the genotypes and haplotypes of these SNPs 
have been found to be potential determinants of interindividual variability in drug disposition 
and pharmacologic response in different types of leukemia. However, due to inconsistencies in 
the results observed across the studies, additional studies, considering novel genomic method-
ologies, comprehensive definition of clinical phenotypes, adequate sample size, and uniformity 
in all the confounding factors, are warranted.
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Introduction
Leukemia, a group of cancers that start in blood forming cells of the bone marrow, 
can affect anyone, including children. By considering whether leukemias are acute or 
chronic, and whether they are myeloid or lymphocytic in origin, they can be divided into 
four main types: acute myeloid leukemia (AML), chronic myeloid leukemia (CML), 
acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Acute 
leukemias have many subtypes that vary in the response to treatment. Treatment of 
leukemias depends on the type of leukemia, certain features of the leukemia cells, 
the extent of the disease, prior history of treatment, as well as the age and health of 
the patient.1,2 The genetic profile or specific characteristics of the leukemia cells as 
determined in the laboratory are used to determine the type of treatment that may be 
most appropriate. Most leukemia patients are treated with chemotherapy, while some 
may also have radiation therapy, biological therapy, targeted therapy, and bone  marrow 
transplantation.1,2
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Treatment challenges in leukemias
For most cases of AML, treatment is usually chemotherapy, 
which is divided into two phases – remission induction (often 
called induction therapy) and consolidation (postremission 
therapy). Patients with different subtypes of AML can have 
different outlooks and response to treatment. After diagnosis, 
AML patients are categorized into three outcome risk profiles 
(favorable prognosis, intermediate risk profile, and poor 
outcome risk profile) and treated accordingly. However, for 
some unknown reasons, some respond well and some do not. 
Accordingly, adult AML patients have a 25% 5-year overall 
survival (OS) rate, whereas children and teens younger than 
15 years have 66% OS rate.1 New discoveries are needed to 
increase the chances of survival for AML patients who do 
not respond well to treatment.
The understanding of aberrant tyrosine kinase activity 
as the molecular mechanism behind CML development 
led to the development of tyrosine kinase inhibitor (TKI) 
drugs such as imatinib mesylate (IM).3,4 The molecularly 
targeted drug IM has become the gold standard drug for the 
first line treatment of CML. An event-free survival (EFS) of 
86% and OS of 88% for CML patients on IM therapy was 
reported by a 6-year update of the IRIS study.5 Furthermore, 
this resulted in overcoming the difficulties encountered with 
previous therapeutic approaches.3,6 Despite these excellent 
results, approximately 30%–40% of CML patients on IM 
therapy develop resistance.7 In a significant proportion of 
CML patients, achievement of prolonged response to IM is 
still a daunting problem due to development of resistance or 
suboptimal response to IM.
Treatments for ALL patients include chemotherapy, bio-
logical agents, and transplant. Most chemotherapy plans for 
ALL involve three steps which are induction, consolidation, 
and maintenance. Chemotherapy and corticosteroids are in 
the treatment protocols. Different types of ALL patients 
may be treated differently. Younger adults with ALL have 
better long-term survival rates than older adults with ALL. 
Nevertheless, survival rate for childhood ALL have risen 
dramatically during the last 10–15 years and more than eight 
out of ten children are now cured.8 According to National 
Cancer Institute report, the 5-year survival rate for children 
and teens younger than 15 years is 92%, whereas the overall 
5-year survival for ALL is 70%.1
CLL is treated by chemotherapy, radiation therapy, 
therapy using monoclonal antibodies, or bone marrow 
transplantation. Majority of patients follow an indolent 
clinical course with no or delayed treatment need and with 
a prolonged survival, while others experience aggressive 
disease requiring early treatment followed by frequent 
relapses. However, during the last few decades, several new 
chemotherapeutics drugs are being tried, and some of these 
are promising in targeting CLL. For CLL, an OS rate of 84% 
has been achieved with modern treatments.1 Some of the 
available treatments can often induce disease remission, but 
they are not able to reach the cure, and hence CLL remains 
an incurable disease in virtually all cases. So, in CLL,  fur-
ther research on individual factors that can benefit treatment 
regimens need to be undertaken.
Pharmacogenomics of drug 
response
Earlier, most patients with a specific type of leukemia were 
given the same treatment. The realization that some treat-
ments worked better for some patients than for others led to 
research into the genetic differences seen in patients and in 
tumors. The completion of the Human Project in 2003 had 
provided increasingly comprehensive information on the 
genetic variations among individuals that are responsible for 
this variation in treatment response. Genetic variations in the 
form of single-nucleotide polymorphisms that affect gene 
expression or function in both normal and cancer cells can 
cause inherited interindividual differences in the metabolism 
and disposition of medications. Single-nucleotide polymor-
phisms (SNPs) between individuals influence how effective 
and safe a drug is for a person.
Pharmacogenetics incorporates information on how 
inherited genetic variation in a gene can affect a patient’s 
response to chemotherapeutic agents and aims to use this 
knowledge to tailor therapy for improved response and 
reduced toxicity. Meanwhile, pharmacogenomics is a broader 
strategy which elucidates the entirety of pharmacologically 
relevant genes, including the effects of genetic variation in 
single genes, the interaction among genes in biological and 
pharmacological pathways, the phenotype emerging from 
these variations, and the effect of the phenotype on drug 
response.9 Studies of inherited variability in drug targets or 
target pathways, variation in genes encoding drug-metaboliz-
ing enzymes or drug transporters, and genetic polymorphisms 
in genes encoding proteins, all of which indirectly influence 
drug response, comprise the field of pharmacogenomics. It 
also includes how these genetic variations interact to produce 
inherited drug-response phenotypes.10,11 Variations in drug 
metabolizing enzymes, drug transporters, and drug targets 
are the most practical aspects of pharmacogenomics. The 
approach of personalized medicine, which uses predictive and 
prognostic biomarkers to direct patient management, holds 
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great promise in improving the efficiency of treatment and 
outcomes of leukemia patients. In order to realize personal-
ized medicine, there is the need to understand the molecular 
mechanisms underlying interindividual differences in drug 
response, including pharmacological effects and side effects.
Genetic variation and drug 
resistance
Development of resistance to chemotherapeutic drugs, 
which results in treatment failure, is a severe limitation of 
chemotherapy in leukemia patients. Factors that can influence 
plasma and intracellular levels of chemotherapeutic drugs 
may contribute to the development of resistance. Genetic 
polymorphisms in key genes encoding drug transporters 
and drug metabolizing and binding enzymes may influence 
the intracellular delivery and therefore the effectiveness 
and toxicity of chemotherapeutic drugs.12,13 Genetic poly-
morphisms in the form of SNPs that affect gene expres-
sion or function in both normal and cancer cells can cause 
inherited interindividual differences in the metabolism and 
disposition of medications. Accordingly, genetic variations 
of candidate genes could affect expression of corresponding 
proteins and thus may bring about differences in response 
to chemotherapeutic drugs. Given that genetic differences 
between individuals or population can impact the efficacy 
of drugs, defining pharmacogenetic differences among 
patients is regarded as an important aspect which needs to 
be addressed in understanding the development of resistance 
to chemotherapeutic drugs in leukemia patients.
Accumulating evidence strongly suggests that drug 
transporters are one of the determinants governing the phar-
macokinetic profile of chemotherapeutic drugs. Membrane 
transporters play an important role in acquired and de novo 
drug resistance. Based on the direction in which they trans-
port, transporters are often classified as efflux, influx, or bidi-
rectional. Drug resistance mechanism in anticancer therapy 
has been well established by drug transporter  proteins. 
Expression of higher than normal levels of a transmembrane 
protein which serves as an energy dependent efflux pump 
causes a reduction in the amount of drug that accumulates 
within cancer cells and is considered a common mechanism 
of multidrug resistance in cancer cells.14,15 Variation in drug 
transporters is one of the most clinically relevant pharma-
cogenomics aspect of some of the chemotherapeutic drugs 
for leukemias.
In this review, attention is focused on ABC transporters, 
and specifically on currently understood information on the 
impact of genetic variations in ABCB1 gene on leukemia 
treatment that may suggest better strategies in future for the 
use of current therapeutic agents.
ABC superfamily
The ATP-binding cassette (ABC) transporter is a protein 
superfamily whose members are characterized by two highly 
conserved ATP binding cassettes. In the human genome, 48 
different members, forming eight different subfamilies (A–G) 
have been identified, based on sequence similarities.16 The ABC 
superfamily of proteins are involved in the transport of intrinsic 
and extrinsic molecules such as ions, sugars, glycans, phos-
pholipids, amino acids, peptides, proteins, drugs, and toxins. 
Internalization of those substrates such as molecules and drugs 
occurs by active transport, which is dependent on the hydrolysis 
of ATP. All eukaryotic ABC proteins are efflux pumps.
ABCB1 protein
Within the ABC transporter superfamily, the subfamily B 
member 1 (ABCB1) appears to be most important in the 
human body, especially for the disposition of xenobiotics. 
ABCB1 transports a wide range of drugs and xenobiotics 
from the intra- to extracellular compartment at many biologi-
cal interfaces such as the intestine, liver, blood–brain barrier, 
and kidney. As a transporter, ABCB1 has a broad affinity 
spectrum for different anticancer agents such as docetaxel, 
paclitaxel, irinotecan, vincristine, doxorubicin, vinblastine, 
mitoxantrone, teniposide, topotecan, etoposide, imatinib, 
sunitinib, etc.17–19
The ABCB1 gene which codes the ABCB1 protein 
is located on chromosome 7q21.12. It spans 28 exons in 
a genomic region spanning 209.6 kb20 and is one of the 
49 putative members in the superfamily of human ABC 
transporters.21 The messenger RNA (mRNA) is 4,872 bp in 
length, includes the 5’ untranslated region (Ref seq accession 
NM_000 927.3), and can encode a protein of 1,280 amino 
acids in length, which is named the plasma membrane glyco-
protein (P-glycoprotein [P-gp]) which is 170 kDa.20 ABCB1 
was formerly termed multidrug resistance gene (MDR1) 
since P-gp was observed to be overexpressed in tumor cells 
and led to the commonly known phenomenon of multidrug 
resistance against certain antineoplastic agents.21 Being 
involved in the extrusion of amphoteric compounds, it is 
also known as the Traffic ATPase.22 Recently, the common 
ABC transporter nomenclature has been applied in naming 
the gene and protein of P-glycoprotein as ABCB1 (in italics 
and nonitalics, respectively).
One of the main functions of ABCB1 include first- pass 
elimination of orally administered drugs to limit their 
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 bioavailability, by effluxing drugs from the lumen-facing epi-
thelia of the small intestine and colon and from the bile-facing 
canaliculi of the liver. ABCB1 mediated drug disposition is 
influenced by modulation of ABCB1 gene expression and/
or ABCB1 activity by various mechanisms. Overexpression 
of these transporters on plasma membranes cause increased 
efflux and decreased intracellular accumulation of many 
anticancer drugs, leading to multidrug resistance.23
High levels of ABCB1 expression results in decreased 
intracellular concentration of drugs, and this will lead to 
development of cellular resistance to anticancer drugs. The 
expression level and functional integrity of ABCB1 may 
affect its pharmacogenetics and its interaction with drugs. 
Because of this, ABCB1 plays a significant role in drug 
efficacy and toxicity during treatment. Few studies have 
demonstrated that the level of ABCB1 activity determines the 
tissue distribution of drugs and affects the uptake from the 
gastrointestinal tract as well as elimination into urine or bile.16 
Many substrates of ABCB1 have been well documented to 
be potent ABCB1 inhibitors, including channel blockers, 
calmodulin antagonists, immunosuppressants, and protein 
kinase inhibitors.24
The discovery of ABCB1 provided a laboratory model 
that could explain the phenomenon of multidrug resis-
tance. Cancer cells express ABCB1 proteins in different 
levels, thereby contributing to chemoresistance. For a better 
 understanding of the significant variability in response to che-
motherapeutics, polymorphisms in the ABC drug  transporters 
have been extensively studied.
Genetic polymorphisms of ABCB1
Several publications have described polymorphisms of 
drug transporters as potential determinants of variability in 
drug disposition and efficacy. Polymorphisms in key drug 
transporter genes are known to influence intracellular drug 
delivery and, therefore, the effectiveness of drugs. With 
regard to ABCB1 gene also, a number of SNPs have been 
identified that are likely to have an effect on P-gp expression 
levels and function. SNPs in ABCB1 have been reported as 
modulators of ABCB1-mediated transport.
SNPs in ABCB1 have the potential to alter ABCB1 gene 
expression as well as P-gp function. Such SNPs are predicted 
to be associated with changes in both the pharmacokinetics 
and pharmacodynamics of several P-gp drug substrates, treat-
ment response, as well as side effects.25,26 According to NCBI 
SNP database, around 1,200 SNPs have been identified within 
the ABCB1 gene, of which 66 SNPs have been identified in 
the coding sequence so far, while more than 20 are known 
to be silent.27 There is considerable heterogeneity in the 
literature and across the populations regarding the frequen-
cies and association of this transporter gene polymorphisms 
with drug resistance. Among the various population groups, 
three SNPs 1236C>T, 2677G>T/A, and 3435C>T of ABCB1, 
which are located in exons 12, 21, and 26, respectively, are the 
most widely investigated for their clinical implications.28–30
The SNPs C1236T, G2677T/A, and C3435T have been 
reported to be associated with altered mRNA expression 
levels, mRNA stability, and protein folding and influence 
drug pharmacokinetics.31–33 However, another study found no 
association between these SNPs and ABCB1 gene function.34 
Changes in P-gp expression and function would be expected 
to alter the absorption, plasma concentration, tissue distribu-
tion, and excretion of its drug substrates.
The silent 3435C>T (rs1045642) was the first poly-
morphism of ABCB1 to be described and also modify P-gp 
expression.35,36 This SNP modifies the gene expression of 
P-gp without altering the sequence of the protein (wobble 
mutation). However, it is probable that this SNP alters the 
mRNA stability,37 as well as the folding of the protein, 
modifying its substrate specificity. The C3435T is the most 
widely investigated SNP of ABCB1. Differences in variant 
allelic frequency were observed among Caucasian, African, 
and Asian populations.32
The tri-allelic nonsynonymous SNP 2677G>T/A 
(rs2032582) changes the serine to either threonine or ala-
nine. This SNP has been reported to be associated with drug 
response and various diseases and also affects posttransla-
tional modifications.38 Biochemical analysis has confirmed 
that the wild-type G allele of 2677 alters drug transport by 
affecting drug-induced ATPase activity.39 This SNP has been 
detected in various ethnic groups, and the highest variant 
genotype frequency was reported among Japanese (34%) 
compared to South African population, which presented 
only 2%.40,41
ABCB1 1236T>C (rs1128503) encodes for the TM6 
region, which is essential for substrate binding. This third 
most frequent SNP, 1236T>C, has also been reported to affect 
the expression and function of P-gp.29 Highest frequency of 
1236CC variant genotype was observed in German popula-
tion, while lowest was among South Africans, where only 
1% of variant CC genotype was detected.41
Genetic variants closely linked with other variants located 
on the same chromosome, known as haplotype, have also 
been documented to play an important role in drug response 
and disease susceptibility.42 This nonrandom association 
of SNPs is called linkage disequilibrium (LD). Genetic 
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 studies have identified a strong LD between SNPs in exons 
12 (C1236T), 21 (G2677T), and 26 (C3435T).43 Because 
of the significant LD, these SNPs are inherited to form two 
common haplotype patterns (T1236/T2677/T3435 or C1236/
G2677/C3435).29
Frequencies of these SNPs and haplotypes have been 
reported to vary across races and populations.32 Kroetz et al44 
reported 16 variants specific to African Americans, 8 to Cau-
casians, and 3 to Asian Americans. Despite the variant allele 
frequencies being higher in African Americans, the three 
SNPs were reported37 to be twice as common in Caucasians 
as in African Americans. Therefore, ABCB1 substrates may 
be transported differently depending on racial and genetic 
background of individuals.
Owing to the important role in the drug disposition pro-
cess, focus is given on the role of these SNPs as potential 
determinants of interindividual variability in drug disposition 
and pharmacologic response in different types of leukemia.
ABCB1 variants and AML treatment
For all forms of AML in adult patients, a combination of 
cytarabine  and various doses of different anthracyclines 
had been the mainstay of treatment in the last four decades. 
Addition of an occasional third agent to this combination 
chemotherapy regimen has been found to be effective for 
treatment of some AML patients. However, it is far from 
ideal. The traditional ‘one size fits all’ regimen is not appro-
priate for AML. With the current forms of treatment, nearly 
35%–40% of patients younger than 60 years of age are likely 
to achieve long-term survival. However, wide variation in 
outcome among genetically distinguishable subsets of the 
disease has been encountered. Some subtypes show notori-
ously poor outcome. Likewise, the overall prognosis remains 
highly unsatisfactory for patients who are more than 60 years 
of age. Poor prognosis, development of drug resistance, and 
death within 2 years of remission are common presentations 
in most adult AML patients.45 This warrants the need for 
urgent therapeutic improvements in AML.
For a better understanding of the significant variability 
in response to chemotherapeutics, polymorphisms in the 
ABC drug transporters have been extensively investigated in 
AML patients. P-gp expression and activity profile, which are 
influenced by ABCB1 polymorphisms, importantly in exons 
12 and 26, have been documented as factors that contribute 
to AML resistance to chemotherapy.29,46 In AML patients, 
elevated P-gp expression and activity have been considered 
as adverse prognostic factors associated with refractory and 
relapsed disease.47 Furthermore, dosage adjustment has been 
reported to be dependent on ABCB1 polymorphisms, which 
in turn has been implicated to be related to P-gp status.35,48
In AML, complete remission rate and drug resistance 
are related to the function and expression of ABCB1.49 The 
expression and functional drug efflux activity of ABCB1 was 
reported to increase with patient age, from 17% in patients 
less than 35 years old to 39% in patients aged 50 years or 
older.49 Seedhouse et al50 studied the expression and genetic 
polymorphisms of ABCB1 in 817 AML patients. These 
researchers observed that the 3435TT genotype (which 
results in unstable mRNA) of ABCB1 had a significant 
effect on P-gp expression. But this was observed only in 
40% of cases in which mRNA and protein were detectable. 
According to Seedhouse et al,50 low white blood cell count, 
secondary AML, and poor-risk cytogenetics had a much 
higher impact on prognosis than genetic polymorphisms of 
ABCB1 in AML blasts.
In addition, a strong link between ABCB1 genetic variants 
and P-gp expression with poor survival in AML patients has 
been reported.51,52 Scheiner et al51 examined the relationship 
between ABCB1 polymorphism (C1236T, C3435T) and 
P-gp expression activity in 109 Brazilian AML patients to 
understand the possible relationship between these factors 
and their clinical significance. They reported achievement of 
better 5-year OS and 5-year EFS rates in patients present-
ing with genetic variant CC in exon 12, followed by those 
presenting the variant CT in exon 26. According to Scheiner 
et al,51 polymorphisms in the ABCB1 gene and the levels 
of P-gp expression could be useful to identify prognosis in 
AML patients.
Green et al52 and Falk et al53 investigated the influence 
of SNPs 1199G>A, 1236C>T, 2677G>T/A, and 3435C>T 
in Swedish AML patients with de novo normal karyotype. 
Poorer OS was observed in patients with 1236 C/C or 2677 
G/G genotypes than patients with other genotypes (p=0.03 
and 0.02 respectively). Furthermore, leukemic cells from 
1236 T/T and 2677 T/T patients demonstrated significantly 
higher susceptibility to mitoxantrone (p=0.02) and more 
susceptible to etoposide and daunorubicin (p=0.07–0.09) 
but not to cytarabine in in vitro studies.52 In the subgroup 
analysis53 based on FLT3 and NPM1 status of the patients, 
FLT3 wild-type 1236 C/C patients had significantly shorter 
OS compared to patients carrying variant allele (median OS 
20 vs 49 months respectively, p=0.017). Also, those patients 
with FLT3 wild-type 2677 G/G genotype showed an inferior 
outcome, compared to patients carrying the variant allele 
(median OS 20 vs 35 months respectively, p=0.039). These 
researchers concluded that ABCB1 1236C>T and 2677G>T 
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might be used as prognostic markers to distinguish relatively 
high-risk patients in the intermediate-risk FLT3 wild-type 
group of AML patients as part of individualizing treatment 
strategies in future.
In 263 intermediate-risk Chinese AML patients treated 
with anthracycline and cytarabine, He et al54 investigated 
the influence of polymorphisms G2677T/A, C1236T, and 
C3435T. This study reported that patients with TTT hap-
lotype had a longer OS compared with those without TTT 
haplotype, and hence TTT haplotype was possibly related to 
the OS, EFS, and relapse in Chinese patients with AML. In a 
meta-analysis involving seven cohort studies with 1,241 AML 
patients undergoing standard chemotherapy (cytarabine plus 
anthracyclines), Megías-Vericat et al55 reported significantly 
higher OS among carriers of the variant allele of 1236C>T, 
2677G>T/A, and 3435C>T, with Caucasians showing con-
sistent results in OS.
ABCB1 variants and ALL treatment
With the introduction of risk-directed therapy and current 
treatment protocols based on multiagent chemotherapy, the 
survival rates of ALL, especially of childhood ALL, has 
increased significantly. Nearly 85% of ALL patients achieve a 
long-term remission.56 But still, nearly 15% of ALL children 
experience relapse due to substantial variation in treatment 
response.57,58 There is still a group of patients for whom 
therapy fails, and some patients who experience severe toxic-
ity.59 Even though genomic alterations that are somatically 
acquired have long been recognized as hallmarks of ALL, 
inherited genetic variations (germ line) have also emerged as 
important determinants of interpatient variability in treatment 
response and toxicities of ALL patients. Increasing evidence 
that is emerging indicate that inherited genetic variations 
play significant roles in determining patient’s risk of relapse. 
Treatment failures depend on inherited SNPs in genes affect-
ing drug metabolism, transport, and binding site affinity.60
Treatment for childhood ALL involves complex combina-
tion of chemotherapy protocols, and hence individual SNPs 
might not have measurable effects on drug disposition and 
cure rates. Some adverse effects of ALL therapy have been 
linked to specific drugs. Candidate-gene and genome-wide 
approaches have identified inherited variants that may be 
associated with some of the risks of these drug-specific 
adverse effects in ALL.61
Earlier studies by Jamroziak et al62 and Stanulla et al63 
reported better EFS and a lower rate of CNS relapse associ-
ated with the ABCB1 T 3435 allele in childhood ALL. But 
Efferth et al64 and Jamroziak et al65 reported no association 
of this polymorphism with prognosis in adult ALL patients. 
Ceppi et al66 observed that ABCB1 3435TT genotype had 
lower EFS in the discovery cohort in univariate and multi-
variate analysis. However, failure to subsequently replicate 
this finding in a validation patient set has raised arguments 
against the role of this polymorphism in modulation of 
ALL outcome. Erdélyi et al67 examined the association of 
functional ABCB polymorphisms with acute side effects of 
chemotherapy in 138 Hungarian ALL children treated with 
the ALL-BFM-95 protocol. A higher proportion of patients 
who carried the ABCB1 3435TT genotype suffered excessive 
infectious complications than those harboring at least one C 
allele. These researchers concluded that ABCB1 3435T>C 
genotype was associated with the infectious complications 
of applied chemotherapy regimen.
However, single SNPs can have measurable effects if they 
either affect antileukemic agents such as 6-mercaptopurine 
or methotrexate (MTX) that are used extensively in the pro-
tocols,68 or when the gene in question belongs to cytochrome 
P450 family,69 or glutathione S-transferases,70 and potentially 
the ABCB1 gene.
Although MTX is not considered as a P-gp substrate, 
studies of patients on MTX monotherapy by Grabar et al71 
and Kato et al72 showed that the silent ABCB1 polymorphism 
3435C>T might affect outcome and toxicity after MTX 
therapy. In a recent study on 522 Danish children with ALL, 
Gregers et al73 explored the impact of ABCB1 polymorphisms 
1199G>A, 1236C>T, 2677G>T/A, and 3435C>T on the risks 
of relapse and toxicity. They reported that the genetic variants 
1199G>A and 3435C>T were associated with outcome in 
childhood ALL. In the high-risk patients who were carriers 
of 1199 GA variant, an overall relapse rate of >29% and a 
relapse rate of >60% were observed. Gregers et al73 concluded 
that 1199G>A might be a new possible predictive marker for 
outcome in childhood ALL and that patients with 1199G>A 
polymorphism should be observed more intensively. In 
pediatric ALL patients from China, Liu et al74 studied the 
association of 12 SNPs in 4 candidate genes of the MTX/
folate pathway with pharmacokinetics, toxicity, and outcome. 
They reported that long-term outcome was better in ABCB1 
rs1128503T and TC allele carriers than patients with C allele 
(92.7±1.6% vs 78.2±6.6%, p=0.020).
ABCB1 gene is involved in vincristine transport. A candi-
date gene study by Ceppi et al66 demonstrated that variants in 
ABCB1 were associated with vincristine neurotoxicity during 
ALL therapy. The two ABCB1 variations (rs10264856 and 
rs4728709) were reported to be associated with increased risk 
of relapse in childhood ALL patients in a large  genome-wide 
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association study.75 Because these two SNPs are in LD, (but 
not in LD with SNPs at 3435, 2677, or 1236 positions), 
Ceppi et al66 analyzed one of these two SNPs (rs4728709). 
Although no association with EFS or OS was found, they66 
observed protective effect of rs4728709 against lower grades 
of neurotoxicity. From these results, Ceppi et al.66 concluded 
that rs4728709 of ABCB1 (or other SNPs in LD) indeed 
has an impact on ALL treatment outcome, especially on 
vincristine-related neurotoxicity. Substitution (rs4728709) 
in the promoter of the ABCB1 was reported to have a pro-
tective effect against lower-grade neurotoxicity, and C to A 
variation (rs3770102) located 17 nucleotides upstream from 
transcription start site had a protective effect against high-
grade neurotoxicity.66 In another study by Zqheib et al76 on 
127 Lebanese ALL patients, a statistically significant associa-
tion was found among neutropenia (absolute neutrophil count 
<500) and variant allele carriers of ABCB1 rs1045642 and 
ABCB1 rs1128503. According to these authors, genotyping 
for ABCB1 polymorphisms might be useful in identifying 
patients at risk of increased MTX toxicity, which warrants 
the need for dose optimization before treatment initiation. 
On the contrary, candidate gene studies by Kishi et al77 and 
Guilhaumou et al78 observed no association of ABCB1 vari-
ants and vincristine neurotoxicity.
Hence, it is probable that polymorphisms in ABCB1 gene 
may affect intrinsic blast resistance and pharmacokinetics of 
several drugs used in ALL protocols, thereby affecting the 
efficacy of treatment and EFS.
ABCB1 variants and CML treatment
Although targeted therapy with IM demonstrates high 
efficacy in most CML patients, nearly 35%–40% of CML 
patients on IM therapy develop resistance to IM. Resistance 
to IM could be due to a heterogeneous array of mechanisms 
involving BCR/ABL-dependent pathways and BCR/ABL-
independent pathways.78,79 BCR/ABL-dependent mechanism 
generally includes point mutations within the BCR/ABL 
kinase domain that interfere with IM binding and also 
overexpression or amplification of the BCR/ABL gene. 
Among BCR/ABL-independent mechanisms, a number of 
factors may influence the plasma and tissue levels of IM and, 
under certain circumstances, contribute to pharmacologic 
resistance. The efficacy and toxicity of IM seem to depend 
on both IM pharmacokinetics influenced by several enzymes 
and transporters, and IM pharmacodynamics influenced by 
mutational studies of the target. Recently, great attention has 
been focused on interpatient pharmacokinetic variability, 
which is due to patient’s inherent genetic constitution, as 
a BCR/ABL-independent mechanism mediating resistance 
to IM.
Drug exposure below the target level could lead to IM 
levels that are insufficient to inhibit BCR/ABL and to achieve 
optimal response. Of the varied reasons, aberrant expression 
of drug transporters also accounts for IM resistance. Poly-
morphisms in ABCB1 are likely to influence intracellular 
drug delivery, and therefore the effectiveness of IM which is 
a substrate of the P-gp-mediated efflux. Because of the same 
reason, ABCB1 SNPs could affect IM’s bioavailability and 
consequently the treatment outcome of IM therapy, which 
partially explains variable responses to IM.80,81
SNPs in ABCB1 have been demonstrated to display high 
affinity for IM and confer IM resistance in vitro by extrud-
ing IM from hematopoietic cells.82,83. ABCB1 polymorphisms 
were hypothesized to be functional polymorphisms altering 
mRNA stability, modifying the P-gp expression and therefore 
reducing IM substrate specificity.
In Indian CML patients, Sailaja et al84 reported a higher 
frequency of 3435TT genotype in minor/major cytogenetic 
response (CyR) group compared to non-CyR group, but the 
overrepresentation of 3435TT genotype was statistically not 
significant. Dulucq et al85 reported that the distribution of 
3435C>T genotypes was not significantly associated with 
MMR (p=0.20) in Caucasian CML patients. Angelini et al86 
also recapitulated that the 3435CC genotype was significantly 
associated with complete molecular response among Cauca-
sian CML patients. In this sense, the T allele has lower ABCB1 
transcript levels compared to the C allele, and contributes 
to better IM response. On the contrary, a higher risk for IM 
resistance was reported for CML patients with homozygous 
T allele at 3435 locus.87 Maffioli et al88 also demonstrated 
inadequate response or failure to IM treatment associated 
with 3435TT genotype. Studies conducted on Malaysian 
CML patients had shown no relationship between 3435C>T 
polymorphism and response to a standard dose of IM.89 In 
a recent study by Salimizand et al,90 CML patients with C 
allele of ABCB1 C3435T had poor cytogenetic response and 
TT3435 ABCB1 diplotype was significantly associated with 
accelerated phase of CML. This study also indicated that 
CML patients with TT3435 ABCB1 might be having weaker 
response to IM therapy.
It has been reported90 that the ABCB1 2677 G>T/A single 
nucleotide substitution strongly affects the secondary struc-
ture of ABCB1 mRNA. A decrease in P-gp expression could 
result in higher intracellular concentration of IM. Although 
Dulucq et al91 observed a higher frequency of MMR in 
patients with non-G genotypes at position 2677, they could 
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not confirm these results in a larger patient cohort later,85 The 
ABCB1 2677 variant was associated with MMR in Malay-
sian CML patients.89 For ABCB1 2677 T/A polymorphism, 
a better complete cytogenetic response was observed for 
patients with variant TT/AT/AA genotypes compared to 
other genotype groups. Almost similar with the findings of 
Au et al,89 a better CCyR rate was observed among patients 
with ABCB1 2677 GA/AT/AA genotype in the study by Ni 
et al.87 This has been attributed to the fact that carriers of 
the 2677 variant genotype tend to have lower P-gp mRNA 
expression than those who had 2677 wild-type genotype91 
Galimberti et al92 examined the role of ABCB1 SNPs with 
IM resistance by conducting a study which comprised of 33 
CML patients treated with IM. This study showed that CML 
patients who did not achieve at least major cytogenetic remis-
sion had higher levels of ABCB1 expression.92 Elghannam 
et al93 investigated the association of G2677T SNP with IM 
response in Egyptian CML patients. Multivariate analysis 
showed GT genotype to be an independent risk factor for 
resistance, while TT genotype was found to be a protective 
factor against resistance to IM. So, G2677T polymorphism 
might be useful in response prediction to therapy with IM 
in CML patients.
In Malaysian CML patients on IM therapy,89 resistance 
was significantly higher among patients homozygous for 
the ABCB1 1236CC genotype, compared to patients with 
good IM response. The result from the study by Au et al89 is 
in accordance with the findings of Deenik et al,94 in which 
patients with homozygous ABCB1 1236TT showed a higher 
probability of obtaining MMR.
In contrast, in the study by Ni et al87 on the impact of these 
SNPs on IM response, the number of T alleles at loci 1236 
and 3435 were found to correlate with resistance. Resistance 
was higher in those CML patients who were homozygous for 
the 1236T allele, compared to patients with CT/CC genotype 
groups. With regard to 2677T/A polymorphism, a better com-
plete cytogenetic remission was observed for patients with 
genotypes AG/AT/AA compared to TT/GT/GG genotypes. 
In the case of C3435T polymorphism, patients with 3435TT/
CT genotypes showed a higher resistance compared with 
patients with CC genotype. On the contrary, in the study by 
Maffioli et al,88 the CC genotype of C3435T was associated 
with primary failure, whereas T allele of G2677T/A seemed 
to protect from priamry failure.
In a meta-analysis by Zu et al,95 a significant association 
between C1236T polymorphism and increasing risk of IM 
resistance in Asian CML patients was observed. However, 
they noted no significant association for G2677T or C3435T 
polymorphism in Asian populations as well as Caucasian 
CML populations. Zheng et al96 conducted a meta-analysis 
that combined data from 12 reports and included 1,826 
patients. This meta-analysis showed that the 2677G allele 
or 3435T allele predicted a worse response to Imatinib in 
CML patients, whereas 1236CC genotype was associated 
with better response in CML patients from the Asian region. 
These reports suggest the usefulness of these three SNPs of 
ABCB1 as predictive markers for the therapeutic use of IM 
in CML patients.
ABCB1 haplotypes and IM resistance
At haplotypic level, 3435C>T is in strong LD with 1236C>T 
and 2677G>T/A, forming two major haplotypes of 
1236C/2677G/3435C and 1236T/2677T/3435T with abun-
dant frequencies. ABCB1 1236T/2677T/3435T haplotype 
was correlated to higher IM pharmacokinetics trough levels 
in CML patients.91,97 In haplotype analysis of these three 
SNPs of ABCB1 in Malaysian CML patients on IM therapy, 
Au et al89 observed that the wild-type ABCB1 haplotype 
1236C/2677G/3435C was associated with IM resistance, 
which is in agreement with a report by Dulucq et al91 in 
Caucasian population. On the other hand, Maffioli et al88 
found a correlation between 1236C/2677G/3435C haplotype 
and IM resistance. In yet another study,98 none of the ABCB1 
haplotypes had any major influence on the efficacy of IM 
in K562 cells. An explanation to these contradictory results 
could be that these three ethnicity-related SNPs may have 
different distribution of genotype and haplotype frequencies 
when examined in different populations.
Ali and Elsalakawy99 genotyped the three SNPs (C1236T, 
G2677T and C3435T) in 100 Egyptian CML patients under-
going IM therapy. They found that the optimal response 
rate did not differ significantly between C1236T, G2677T, 
or C3435T genotypes. However, optimal response was 
significantly different among patients with the CGC, TTT, 
TGC, CGT, TGT, CTC, CTT, and TTC haplotypes. The 
1236T/2677G/3435T haplotype was significantly associ-
ated with lower probability of achieving optimal response. 
According to these authors, ABCB1 SNPs haplotype analy-
sis should also be taken into account in order to get clearer 
insights into who is likely to respond optimally to IM for 
identifying CML patients who may not respond optimally to 
standard dose IM therapy and potentially need an individual-
ized therapeutic approach.
In another recent study, Eadie et al100 investigated whether 
early increase in ABCB1 mRNA expression (fold change 
from diagnosis to day 22 of IM therapy) could predict patient 
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response. Patients exhibiting a high fold rise were signifi-
cantly less likely to achieve early molecular response, and 
major molecular response, even when switched to nilotinib 
therapy. According to Eadie et al,100 an increase in levels of 
ABCB1 mRNA may serve as easily translatable early warning 
assay for loss of response/development of resistance to IM 
and could serve to identify poor responders who may ben-
efit from the addition of ABCB1 inhibitor to their treatment 
regimen or from switching to alternate therapies. This study 
highlights the importance of drug efflux transporters and 
indicates that ABCB1 mRNA levels may provide a valuable 
prognostic biomarker.
The most likely explanation for the association of 
ABCB1 with IM resistance could be that ABCB1 acted as 
the transporter for IM. Overexpression of P-gp at the cell 
surface reduces intracellular IM concentrations and leads to 
ineffective levels of the IM upon reaching its target.101 Thus, 
increased ABCB1 levels would lead to reduced IM intracel-
lular levels, impaired BCR-ABL inhibition, and ultimately 
resistance to IM treatment.
There is paucity of information available regarding the 
impact of these SNPs on other tyrosine kinase inhibitor 
drugs used in CML treatment. Dessily et al102 investigated the 
impact of expression of ABCB1 1236C>T, 2677G>T/A, and 
3435C>T polymorphisms on the antiproliferative effects of 
imatinib, nilotinib, dasatinib, and ponatinib using K562 cell 
lines. They observed resistance of K 562 
C-G-C 
to IM compared 
with K 562 
C-G-T,
 K 562 
C-T-T 
at clinically relevant concentrations. 
They demonstrated that the wild type protein (ABCB1 
C-G-C
) 
exported IM more efficiently and thus conferred higher resis-
tance to IM compared to the variant protein (ABCB1 
T-T-T
). 
Consistently, in cells expressing the variant protein, IM 
intracellular concentrations were also significantly higher 
than in cells expressing wild-type protein. These results not 
only suggest that the variant haplotype decreases IM trans-
port by ABCB1 but also provide an explanation for previous 
studies that associated the wild-type haplotype (CGC) to IM 
resistance.89,91,95,96 In contrast with IM, these polymorphisms 
did not affect intracellular concentrations of nilotinib and 
also demonstrated limited influence on the antiproliferative 
effects of nilotinib, dasatinib, and ponatinib. These results 
suggest that the ABCB1 SNPs 1236C>T, 2677G>T/A, and 
3435C>T significantly affect the antiproliferative activity 
and intracellular concentrations of IM, but not, or to a much 
lesser extent of nilotinib, dasatinib, and ponatinib.
In most of the studies, only the ABCB1 1236T>C 
and ABCB1 2677G>T/A genotypes and ABCB1 1236C/ 
2677G/3435C haplotype were found to be  significantly 
associated with IM response, whereas the other SNPs did 
not show any significant association. This could be attrib-
uted to several factors. ABC transporters are subjected to 
drug–drug interactions and to regulation by intracellular 
receptors, cytokines, and epigenetic factors. It has to be noted 
that overexpression of ABCB1 is partly mediated by nuclear 
receptors like the pregnane X receptor. Also, suppression of 
micro RNAs also have been shown to lead to an upregula-
tion of ABCB1.
ABCB1 polymorphisms and CLL 
treatment
For CLL, there are many current first-line treatment options. 
The choice of treatment depends on the stage of the disease, 
the patient’s symptoms, the age and overall health of the 
patient, and the benefits vs side effects of treatment. In a 
study on CLL patients, Jamroziak et al103 found highest P-gp 
activity in the carriers of the 3435CC genotype followed by 
intermediate activity in 3435CT heterozygous subjects and 
the lowest activity in the carriers of 3435TT genotype. From 
the above findings, these authors concluded that genotype-
related differences in P-gp activity in B-CLL tumor cells may 
have implications for response to chemotherapy with P-gp 
transported anticancer agents.
Dong et al104 did not find any association of SNPs 
C1236T, G2677T/A, and C3435T of ABCB1 with clinical 
prognostic factors in Chinese CLL patients. Penna et al105 
evaluated whether the SNPs G2677T and C3435T provided 
any prognostic information on the clinical progression of 
B-CLL. The G2677T SNP was associated with the prognostic 
patients’ characteristics and poor prognosis, whereas C3435T 
showed no association with CLL prognosis. According to 
Penna et al,105 ABCB1 heterozygosis may lead to a different 
functional capacity of the encoded protein and to a differ-
ent mRNA expression with respect to homozygous state. 
Moreover, mutant heterozygous G2677T genotype could be 
clustered nonrandomly and nonuniformly (LD) with other 
genes that are able to induce a worse prognosis. These find-
ings support the importance of considering ABCB1 poly-
morphisms as prognostic markers in patients with B-CLL 
in defining a more individualized prognosis and helping to 
identify patients who are at risk of rapid progression.
The conflicting findings reported in the literature could 
be attributed to several factors. Difference in demographic 
data from subjects selected for the various ABCB1 SNPs, 
especially difference in genetic background of the study 
subjects across the populations worldwide, could be an 
important factor. Likewise, difference in study design and 
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sample size among the studies and different genotyping 
methods employed across studies also might be contribut-
ing. Moreover, strong LD between the SNPs and different 
unobserved causal SNPs in different study populations also 
may provide a plausible explanation for conflicting reports on 
association of the SNPs studied with IM response. Accord-
ing to Marchetti et al,106 the methods used to measure P-gp 
expression in various studies, route of drug administration 
and extent of metabolism relative to P-gp-mediated transport, 
environmental factors including difference in dietary constit-
uents among different populations that influence transporter 
function, involvement of other transporters, and associated 
genetic variability also contribute to the inconsistency in the 
reports worldwide. Noninclusion of haplotypes in several 
studies is another major factor of concern for contradictory 
reports. Therefore, more in-depth studies and increasing 
knowledge on function, regulation, and genetic variation of 
transporters are warranted, which can contribute to a better 
understanding on divergent results obtained.
Conclusion and future implications
There is accumulating evidence that treatment outcome in 
leukemias can be influenced by germ line polymorphisms 
that affect drug disposition and/or pharmacodynamics and 
that these effects may explain some of the variability in treat-
ment outcome that cannot be explained by the genotype and 
phenotype variation in leukemic clone. Therefore, genetic 
variation in ABCB1 is of tremendous clinical interest in the 
pharmacokinetics of commonly used antileukemic drugs and 
in multidrug resistance.
The World Health Organization (WHO) classification107 
has included an increasing amount of new clinically relevant 
genomic information for the implementation of precision 
medicine programs. Few polymorphisms and haplotypes of 
ABCB1 have been associated with alterations in drug dis-
position and drug response, including adverse events with 
various ABCB1 substrates in different ethnic populations. 
These SNPs account for the interindividual differences in 
pharmacokinetics and clinical response of selected anti-
leukemic drugs. But the data yielded are not in distinct and 
unconfined reproducible outcomes and are not yet conclusive 
enough to translate pharmacogenetic tests to clinical practice. 
In this context, ABCB1 transporter polymorphisms are not 
yet suitable to be used as biomarkers to predict therapeutic 
response in leukemias and so have not been included in the 
WHO classification. New biomarkers and pharmacogenetic 
tests are emerging only, and based on these, novel treatment 
protocols that are personalized to the genotype needs to be 
designed.
For a complete understanding of the contribution of 
genetic variability in ABCB1 and treatment response and 
toxicity in leukemias, additional studies involving larger 
sample sizes and stratification according to haplotype need 
to be carried out. Because of the known interpopulation dif-
ferences in drug response, factors such as variability among 
ethnic groups, characterization of variability in haplotype 
structure, LD and recombination within and among ethnic 
populations, etc, should also be considered. It would also be 
ideal to carefully consider uniformity in demographic data 
of the subjects selected, sample size, environmental factors, 
and standardization of assays relating to ABCB1 mRNA and 
protein detection and quantification. Hence, future research 
activities, considering novel genomic methodologies such as 
deep sequencing approaches (next-generation sequencing),108 
and a comprehensive definition of clinical phenotypes based 
on a representative and valid sample size calculation,19,109 
to elucidate the impact of rare ABCB1 variants and their 
potential consequences for effect sizes are warranted. Indi-
vidualized approaches based on pharmacogenomics profile 
of individual patients may offer more efficient and less toxic 
therapy to leukemias in the future and can lead to personal-
ized approaches to diagnose and treat patients.
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